The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

This study is currently recruiting participants.

Verified by Emory University, November 2007

Sponsors and Collaborators:	Emory University Bristol-Myers Squibb
Information provided by:	Emory University
ClinicalTrials.gov Identifier:	NCT00209027

Purpose

The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.

Condition	Intervention
Schizophrenia	Drug: Aripiprazole (drug)

MedlinePlus related topics: Schizophrenia

Drug Information available for: Aripiprazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia

Further study details as provided by Emory University:

Primary Outcome Measures:

fMRI data on a monetary reward task after 12 weeks of treatment [ Time Frame: 3 months ]

Secondary Outcome Measures:

Cognitive performance and symptom ratings after 12 weeks of treatment [ Time Frame: 3 months ]

Estimated Enrollment:	30
Study Start Date:	April 2005
Estimated Study Completion Date:	December 2008

Intervention Details:

cross titration from prior antipsychotic to aripiprazole 30mg po qd

Show Detailed Description

Eligibility

Ages Eligible for Study:	20 Years to 50 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Subjects with Schizophrenia:

Inclusion Criteria:

Diagnosed with schizophrenia
Male
Age 20-50
Right handed

Exclusion Criteria:

No current or past drug or alcohol problems (dependance or abuse)
Not color blind

Control Subjects:

Inclusion Criteria:

Male
Age 20-50
Right handed

Exclusion Criteria:

No current psychiatric problems
No current or past drug or alcohol problems
Not color blind

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00209027

Contacts

Contact: Bill Boshoven, BS

(404) 321-6111 ext 6982

bill.boshoven@emory.edu

Locations

United States, Georgia
Atlanta VA Medical Center	Recruiting
Decatur, Georgia, United States, 30033
Contact: Bill Boshoven, BS 404-321-6111 ext 6982 bill.boshoven@emory.edu
Principal Investigator: Erica Duncan, MD

Sponsors and Collaborators

Emory University

Bristol-Myers Squibb

Investigators

Principal Investigator:

Erica Duncan, MD

Emory University/Atlanta VA Medical Center

More Information

Publications:

Berman KF, Zec RF, Weinberger DR. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry. 1986 Feb;43(2):126-35.

Buchel C, Holmes AP, Rees G, Friston KJ. Characterizing stimulus-response functions using nonlinear regressors in parametric fMRI experiments. Neuroimage. 1998 Aug;8(2):140-8.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.

Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999 Jan;156(1):11-8.

Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov;148(11):1474-86. Review.

Friston KJ, Ashburner J, Frith CD, Poline J-B, Heather JD, Frackowiak RSJ (1995) Spatial registration and normalization of images. Hum Brain Mapp 2:1-25

Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, Ross TJ, Salmeron BJ, Risinger R, Kelley D, Stein EA. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry. 2000 Nov;157(11):1789-98.

Elliott R, Friston KJ, Dolan RJ. Dissociable neural responses in human reward systems. J Neurosci. 2000 Aug 15;20(16):6159-65.

Elliott R, Newman JL, Longe OA, Deakin JF. Differential response patterns in the striatum and orbitofrontal cortex to financial reward in humans: a parametric functional magnetic resonance imaging study. J Neurosci. 2003 Jan 1;23(1):303-7.

Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, Drexler KP. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry. 2001 Apr;58(4):334-41.

Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992 May;13(5):177-84. Review.

Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987 Jul;44(7):660-9.

Wexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, Gore JC. Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry. 2001 Jan;158(1):86-95.

Study ID Numbers:	570-024
Study First Received:	September 13, 2005
Last Updated:	November 20, 2007
ClinicalTrials.gov Identifier:	NCT00209027
Health Authority:	United States: Food and Drug Administration

Keywords provided by Emory University:

schizophrenia
reward
fMRI
Aripiprazole

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Psychotic Disorders
Aripiprazole
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Tranquilizing Agents
Therapeutic Uses
Physiological Effects of Drugs
Psychotropic Drugs

Central Nervous System Depressants
Antipsychotic Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009